17,261 trials
Contiguous Stage II Mantle Cell Lymphoma · Noncontiguous Stage II Mantle Cell Lymphoma · Recurrent Mantle Cell Lymphoma
Primary: Two-year Disease-free Survival — 90 percentage of participants
Prostate Cancer · Recurrent Prostate Carcinoma · Stage IV Prostate Adenocarcinoma
Primary: Number of Participants With Change in PSA Response — 2; 0 Participants
Pertussis · Pertussis Immunisation
Primary: Number of Participants Experiencing Adverse Events of Special Interest (AESIs) — 0; 0; 0; 0 Participants
Kidney Cancer
Primary: Objective Response Rate — 28.3 percentage of participants
End Stage Renal Disease
Primary: Mean Partial Thromboplastin Time (PTT) at 15 Minutes — 38.4; 38.4; 45.4; 49.7 Seconds
Dry Eye Disease
Primary: Mean Change in Schirmer's Test From Baseline to 28 Days — 10.5; 5.7 mm
Lung Cancer
Primary: Toxic Death Rate — NA Participants
Metastatic Melanoma
Primary: Percentage of Participants With Overall Response (OR) — 38 percentage of participants
Critically Ill · Acute Kidney Injury
Primary: Death Within 7 Days — 4; 9; 6 Participants — p=0.52
Stage III Intrahepatic Cholangiocarcinoma AJCC v7 · Stage IIIA Gallbladder Cancer AJCC v7 · Stage IIIB Gallbladder Cancer AJCC v7
Primary: Median Progression Free Survival (PFS) — 11.4; 14.9 months — p=0.62
Nonalcoholic Steatohepatitis (NASH) · Nonalcoholic Fatty Liver Disease (NAFLD)
Primary: Percentage of Participants Who Experienced Treatment-Emergent Adverse Events — 50; 60; 50; 25 percentage of participants
Neovascular Age-related Macular Degeneration
Primary: Systemic Adverse Events — 6; 5; 5; 11 Participants
Multiple Myeloma
Primary: Number of Phase I Patients (Dose Level 1-6) Experiencing a Dose-Limiting Toxicity (DLT) to Determine the Optimal Dosage — 0; 0; 0; 0 Participants
Posttraumatic Stress Disorder
Primary: Change in Clinician-Administered PTSD Scale (CAPS-IV) From Baseline to Primary Endpoint — -11.4; -58.3; -44.3 score on a scale
Systemic Sclerosis
Primary: Change From Baseline in Modified Rodnan Skin Score to Week 24 — -2.45; -4.76 score on a scale — p=0.0291